Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.

Clark, R E

Clark, R E.

Affiliation

Clark RE; University Department of Haematology, Royal Liverpool University Hospital, UK.

Leukemia ; 14(3): 347-55, 2000 Mar.

Article in En | MEDLINE | ID: mdl-10720125

Subject(s)

Antisense Elements (Genetics)/therapeutic use; Fusion Proteins, bcr-abl/genetics; Gene Expression Regulation, Neoplastic/drug effects; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy; Animals; Antisense Elements (Genetics)/chemistry; Antisense Elements (Genetics)/pharmacokinetics; Bone Marrow Purging; Deoxyribonucleases/physiology; Forecasting; Genes, myc; Hematopoietic Stem Cells/drug effects; Humans; Leukemia/genetics; Leukemia/therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Lymphoma/therapy; Mice; Mice, SCID; Neoplasm Proteins/physiology; Neoplastic Stem Cells/drug effects; Proto-Oncogene Proteins c-myc/biosynthesis; RNA, Messenger/antagonists & inhibitors; RNA, Messenger/genetics; RNA, Neoplasm/antagonists & inhibitors; RNA, Neoplasm/genetics; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Gene Expression Regulation, Neoplastic / Antisense Elements (Genetics) / Fusion Proteins, bcr-abl Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2000 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links